JERUSALEM--(Marketwire - January 08, 2009) -
| Highlighted Links |
IDenta Corp. |
The complete text of the letter is as follows:
To The Valued Shareholders and Potential Long-Term Investors in IDenta Corp.:
The war on drugs, crime and terrorism knows no retreat or chance of economic depression. It is, and will continue to be, ever expanding as criminal elements around the world seek new ways to disrupt civilized society causing pain, anguish and hardship. It is truly unfortunate these criminal elements thrive on causing so much unnecessary hardship to millions of people around the world most every day of every year.
During 2008 IDenta Corp. continued its quest to be a world leading innovator and supplier of specialized chemical detection kits that identify dangerous explosives, illegal drugs and assist in the investigation of serious crimes. We take great pride in the products we develop, produce and market around the world that are used to help deter, stop and solve these merciless crimes. We are also proud that we can stand by the promise that all IDenta chemical detection products are the most advanced, safe, inexpensive, user friendly and reliable products available in the law enforcement industry today.
IDenta ended 2008 with revenues exceeding $500,000, which we consider to be a significant milestone because it means that a formidable, reliable base of clients has been established. We are positive this sales base will provide the springboard for rapid customer expansion and revenue increases during 2009. IDenta Corp. is deeply engaged in a worldwide law enforcement industry that continues to increase their budgets and calls for new types of chemical detectors. Therefore we estimate revenues for 2009 will at least double, based on our current sales as well as the projections of our leading affiliates, Jant Pharmacal/Accutest® in the United States, IBTEC in France, SDT in Portugal, SONEX in the Baltic countries, CSI in Canada, etc. The company projects that during 2009 we will exceed $1,000,000 in worldwide sales.
2008 was another strong year for IDenta's research and new product development team. The company introduced the world's first line of detectors for drug precursors (chemicals used to make illicit drugs such as ecstasy, heroin and methamphetamines). This technological innovation was coordinated by IBTEC-France through the urging of the International Narcotics Control Board (INCB) of the United Nations. These products are currently being used by agencies in France and during 2009 we expect to begin bringing these products to other countries including the United States in the near future. They will be significant weapons in the war against drug smuggling and production, and will be a steady contributor to the company's bottom line as large orders are in line for the country of France in 2009.
IDenta's line of Stinger Drug Detectors continues to be the major revenue source for the company. Hundreds of law enforcement agencies have tested and are using regularly, or are currently evaluating, our drug detectors which always prove superior to all other competing products. Recent public admissions by our major competitor that several of their detectors could cause serious injury have bolstered IDenta's promise that we will never produce a product that is deemed in any way to be unsafe to our valued customers. 2009 will be another year which hundreds of law enforcement agencies around the world switch to IDenta drug detectors because they are easier to use, much safer and yield no false positives.
IDenta's five types of explosive detectors which test for the dangerous chemical compounds most used by terrorists are quickly proving their value to military and homeland security operations. The Canadian army has chosen IDenta explosive detectors to help protect the country and insure the safety of its military operations overseas. Inquiries about IDenta explosive detectors and requests for samples have significantly increased the past six months from numerous threatened countries around the world.
Bullet Test Kits (BTK), IDenta's unique kits that assist crime investigators, have been quickly accepted and highly acclaimed by law enforcement agencies. This product has opened many doors for the introduction of other IDenta products to these agencies. Its uniqueness again points to the value of IDenta's R&D efforts, which no other forensic producer has to offer.
In the United States with our partnership with Jant Pharmacal/Accutest® now in full engagement for one year, progress has been nothing less than exemplary. Their introduction of the new Accutest® IDenta Drug Identification Training Program educates, trains and certifies patrol and narcotics officers in the use of the Accutest® IDenta Drug Identification Field Test Kits. The training certification program not only ensures competency in the use of the kits, but generates widespread acceptance and product sales to law enforcement agencies. It is the strategic advantage that shows IDenta/Accutest® is dedicated to not just selling products, but tightening the legal loopholes that have allowed dangerous criminals back on the street.
Certification programs are currently underway in law enforcement agencies, police departments, and drug task forces in multiple states. Our goal for 2009 is to graduate 2500 officers nationwide through this program. We are convinced that our partnership with Jant Pharmacal, www.accutest.net, is the most significant business decision we have made since IDenta started. With their network of over 30 professionally trained and equipped U.S. distributors, with more coming on line in 2009, we are winning over new customers every day.
On the European front our partnership with IBTEC in France has also yielded solid results and broad international exposure. The orders from France and Portugal alone in 2009 have the potential to exceed $500,000 in sales. The 2008 marketing model developed to research and strategize new marketplaces will be applied as we embark on expanding during 2009 into the United Kingdom, Spain, Argentina, Southeast Asia, South Africa, Benelux, Scandinavia, India and Singapore. In our home country of Israel we have reinforced our already strong law enforcement network, and expect to increase sales of existing products and be called on to develop of new detector tools.
IDenta will be launching a new commercial website in early 2009 to promote the sale of drug detectors directly to consumer, schools, business and civil marketplaces around the world. The ability of this website to open new sales channels for drug detection products will be dependent upon:
1. The level of promotion that the company engages and sustains. 2. The refinement of offerings on the website to match the interests of the marketplace (based on the website visitor statistics) 3. The true marketplace need and demand for products of this nature.
The initial investment of this site is relatively modest compared to the potential revenues that may be generated for years to come. A major announcement will be made when the site is made available for public view and promotion.
Last I would like to share a few personal words to our loyal long-time investors and potential new long-term investors -- beware the small-cap company that promotes its stock more than it promotes the sale of its products. The small cap industry, pink sheet stocks in particular, has unfortunately been tainted by multitudes of false claims, promises and stock promotions which have been conducted only for the benefit of raising money for a few promoters with no real regard for investors. Your investment in IDenta Corp. is an investment in a company with not only excellent products that are winning in world-wide marketplaces, but it is an investment in competent, dedicated and honest management with no interest at all in creating a false investing environment. This integrity we believe must guide our every decision.
IDenta Corp.'s Board of Directors stands by its long-standing promise to make business decisions which are only intended to enhance long-term corporate value and continue our history of marketplace leadership. This past year, for instance, all of the expansion of company marketing activities, enhancement of our production line and all of our R & D without acquiring any new corporate debt. In fact, the company is virtually free of all long-term debt at this time.
IDenta's Board of Directors has therefore begun to discuss with professional counsel the requirements and steps that will be necessary for IDenta to start on a path to move the company stock from the Over-The-Counter trading floor to the NASDAQ small cap arena. Numerous events and benchmarks must be met for this to occur but we nevertheless know that this must be the vision for IDTA stock. It will raise the company above the interests of those who only seek to interfere with establishing a true market value for IDenta Corp.
I encourage our current shareholders to spread the word because to meet the future requirements for corporate elevation we must expand our shareholder list. We stand by the representation that IDenta will not produce products which could cause harm to our valued customers. We also are committed to insuring the best value, current and future, for our investors. I am calling on all vigilant investors to remain confident that your modest investment in IDenta has the realistic potential for significant returns.
DISCLAIMER
Certain of the statements contained herein may be, within the meaning of the federal securities laws, "forward-looking statements" that are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on management's expectations as of the date hereof, and the company does not undertake any responsibility to update any of these statements in the future.
For Investor Relations, lobbying interests or information concerning IDenta's products internationally or the development of new chemical detectors, contact: Yaacov Shoham, IDenta Corp., CEO, Tel: +972-52-6554487, fpi@drugsdetector.com. www.IDenta.biz
For Investor Relations in the US, contact: Randy Jacobs, Corporate Spokesman, IDentaNews@sitcomllc.com, 1-800-316-9437.
For information about the Accutest® -- IDenta products in the US, please
contact: Mr. Eyal Golan, COO, JANT PHARMACAL CORPORATION, 16255 Ventura
Blvd. #505, Encino, CA 91436, Toll Free: 800-676-5565, 661-478-0582
(mobile), golan@accutest.net, www.accutestIDenta.net.
